𩺠å
§ç§å°ç§èåç
ð äžé éé»
- 22E: pre-emptive PGx panel emerging, EHR-integrated decision support
- Taiwan: HLA-B1502 / B5801 åå®¶å¥ä¿æ¶µè
- DPYD testing for 5-FU 挞æ®å
ð é²é
Pre-emptive PGx Panel
- äžæ¬¡é©å€åºå ïŒåæª EHR
- èæ¹æèªå alert
- VA, Mayo, Geisinger 已寊æœ
- å°ç£é«åžäžå¿è©Šè¡
CPIC Guideline Highlights (2024)
- HLA-B*1502 + carbamazepine: avoid
- HLA-B*5801 + allopurinol: avoid (CDS alert recommended)
- TPMT + thiopurine: dose adjustment table
- DPYD + fluoropyrimidine: 50% dose reduction or avoid
- CYP2C19 + clopidogrel: ticagrelor/prasugrel for LoF
- CYP2C19 + voriconazole: dose adjustment
- CYP2D6 + codeine/tramadol: avoid in PM/UM
Beyond Single Gene
- Polygenic risk score (PRS) for warfarin
- AI-guided dosing integration
- EHR clinical decision support alerts
ð Pearls (10)
- HLA testing äºæŽ² mandate for carbamazepine
- NUDT15 > TPMT in äºæŽ² thiopurine
- Pre-emptive PGx panel at ICU/oncology emerging
- DPYD 4 SNPs standard testing
- CYP2D6 copy number variation important (UM, PM)
- CPIC guidelines updated regularly
- **HLA-B*5701** > 99% NPV for abacavir HSR
- Tamoxifen + CYP2D6 breast cancer outcome
- Methylene blue avoid in G6PD def
- AI + PGx + EHR is future of precision dosing
ð ç¹æ®æ
å¢
Pre-emptive Panel Implementation
- VA Genomic Medicine Service
- Mayo Clinic Center for Individualized Medicine
- Geisinger MyCode
- Taiwan: éšåé«åžäžå¿è©Šè¡
Pediatric PGx
- TPMT/NUDT15 in childhood ALL
- HLA-B*1502 in pediatric epilepsy
- Codeine FDA contraindication < 12 yo
Oncology PGx
- DPYD + 5-FU
- UGT1A1 + irinotecan
- TPMT + thiopurine in ALL
- HLA-A*3303 + flucloxacillin
- HLA-B*5601 + clozapine
ð Taiwan
- å¥ä¿ HLA-B*1502 carbamazepineïŒ2010+ïŒ
- å¥ä¿ HLA-B*5801 allopurinol æ¢ä»¶çµŠä»
- NUDT15 testing emerging
- å家粟æºé«çèšç«æšå»£
- TFDA pharmacogenomic labeling
ð å
§å°éé»
- 5 å PGx pairïŒäºæŽ²å¿
èïŒ
- CPIC guidelines
- Pre-emptive panel
- DPYD/UGT1A1 oncology
- Taiwan å¥ä¿ testing
â ïž AI èçš¿ã